The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Subscribe To Our Newsletter & Stay Updated
